The most-talked-about peptides of 2026 — vs. what the evidence supports

Every “trending peptides” list ranks how much people talk. That's useful for spotting what people care about — and useless as proof of anything. So we flipped the question: for 27 compounds, we counted who sells them and how much buzz they get, then graded every single source behind them, from peer-reviewed papers down to vendor marketing.

By The Health Stacks Research Team

5 findings anyone can quote

13%

of BPC-157's 534 indexed sources are peer-reviewed — yet 292 suppliers sell it, the most-hyped compound we checked

2 of 284

retatrutide's sources are peer-reviewed — 481 distinct claims circulate about it, carried by 180 suppliers

82% vs 3

of secretin's sources are peer-reviewed (its claims average a 79.5/100 evidence score) — and just 3 suppliers carry it

11–6–10

compounds land in one of three buckets: hyped but thinly sourced, proven but quiet, or popular and well-evidenced

Two scores per compound: attention and evidence

Attention counts everything said about a compound anywhere we looked — forum threads, vendor pages, YouTube, news, and published research alike. Evidence is stricter: what share of those sources are peer-reviewed papers or clinical guidelines, and how the compound's individual claims score when every claim is graded by its source (a claim can never score above the source it came from).

The gap between the two is the story. A compound can be everywhere commercially while the actual published record behind it stays thin — or the reverse.

Everywhere you look, thinly sourced

These are the compounds the market talks about most — each carried by 80+ suppliers, yet under 20% of their indexed sources are peer-reviewed. Being here doesn't mean a compound does nothing; it means the loudest claims about it mostly aren't coming from published research.

Compound	Suppliers selling	Sources indexed	Peer-reviewed share	Peer-reviewed	Avg claim score
BPC-157	292	534	13%	71	46/100
TB-500	226	156	13%	20	42/100
Ipamorelin	198	142	14%	20	38/100
Tesamorelin	193	261	9%	24	46/100
Retatrutide	180	284	1%	2	52/100
MOTS-c	176	89	9%	8	47/100
Sermorelin	164	225	16%	37	42/100
CJC-1295	140	177	15%	27	39/100
KPV	123	131	5%	7	46/100
GHRP-2	94	111	16%	18	44/100
LL-37	82	100	7%	7	54/100

Retatrutide is the sharpest example: 481 distinct claims in circulation, two peer-reviewed sources. Tesamorelin, KPV, and MOTS-c sit in the same pattern — real commercial footprints, single-digit peer-reviewed shares.

Proven in the literature, quiet in the market

The mirror image: compounds where most sources are peer-reviewed — some approved medicines with decades of use — but almost no gray-market footprint. Under-discussed isn't a recommendation; it just means the evidence and the buzz point in opposite directions here too.

Compound	Peer-reviewed share	Sources indexed	Peer-reviewed	Suppliers selling	Avg claim score
Vasopressin	88%	172	152	8	54/100
Secretin	82%	152	124	3	80/100
Insulin	79%	1,558	1,230	14	72/100
Calcitonin	74%	168	125	5	61/100
Follistatin	71%	123	87	17	41/100
Neuropeptide Y	62%	143	88	3	69/100

Insulin is the extreme: 1,230 peer-reviewed sources — and a prescription-only supply chain, which is exactly why almost no research-chemical vendors list it.

Popular and well-evidenced

The healthy quadrant: real commercial presence and a substantial published record behind it — at least 40 peer-reviewed sources each. Note the two columns can still disagree: semaglutide and tirzepatide have hundreds of peer-reviewed sources in absolute terms while their share stays low, simply because commercial chatter about them dwarfs the literature.

Compound	Suppliers selling	Peer-reviewed	Peer-reviewed share	Avg claim score
Thymosin Alpha-1	76	216	44%	56/100
Oxytocin	83	199	68%	49/100
Semaglutide	306	175	13%	56/100
Tirzepatide	291	101	14%	54/100
DSIP	109	84	82%	76/100
NAD+	142	82	89%	62/100
GHK-Cu	307	75	29%	46/100
Semax	137	66	30%	44/100
Bremelanotide	169	49	29%	45/100
SS-31	78	47	41%	52/100

How to use this

Popularity is a question, not an answer. A compound trending on forums tells you what people are curious about. Before acting on any claim about it, look at where the claim comes from — the source grade is the difference between “a study showed” and “a seller says.”

Low share isn't a verdict. New compounds (retatrutide is the obvious one) sit low partly because their research is young. The scoreboard tells you what's proven today, not what will be proven next.

Every number here links to its evidence. Each compound page shows its claims with the source behind every one — follow any figure on this page to the paper, guideline, or page it came from.

Methodology & limitations

Compounds are all researched compounds published in our knowledge base with at least 80 indexed sources. “Sources” are distinct documents — peer-reviewed papers, clinical guidelines, news articles, specialist forum threads, and vendor pages — each graded from peer-reviewed (highest) to vendor marketing (lowest). “Peer-reviewed share” counts the PeerReviewed and ClinicalGuideline grades. Claim scores average each compound's individually graded claims on a 0–100 scale, where a claim can never score above its source. Supplier counts reflect supplier product listings in our index as of 2026-08-25. Buckets are threshold rules applied to these two axes — widely-sold means 60+ suppliers; “thinly sourced” means under 20% peer-reviewed share with fewer than 100 peer-reviewed sources. Approved medicines with large absolute literatures can show a low share simply because commercial coverage dwarfs the science; we separate those into the well-evidenced bucket on absolute count.

Every figure on this page is traceable to a real, crawled source. Nothing is model-fabricated. This report is educational and not medical advice.

Educational content only. The Health Stacks does not provide medical advice. Peptides discussed on this site are not FDA-approved for human use unless explicitly stated. Always consult a qualified healthcare professional before use.

← Back to The Health Stacks